Biotech news
Biotech
ERS Genomics, founded by CRISPR co-inventor Emmanuelle Charpentier, celebrates as China rejects invalidity challenges | News follows on heels of a similar Japan Patent Office decision. 26 March 2024
Biotech
It is critical that the emerging field of personalised medicine receives appropriate patent protection, explain Joel Coles and Theo Cooper of Powell Gilbert. 14 March 2024
Biotech
US medical device company alleges Catalyst Orthoscience infringed patent through reverse shoulder surgery system | Firm seeks to enforce a patent granted in October last year. 29 February 2024
Biotech
UPC overturns previous decision barring NanoString from selling CosMx products in 17 European countries | Court did not stay proceedings on account of NanoString’s Chapter 11 filing. 27 February 2024
Biotech
DePuy Synthes tries to overturn a ruling over knee replacement device | Challenges the court's decision, including ownership disputes, interpretation of critical terms, and the granting of a permanent injunction. 27 February 2024
Biotech
Agreeing to a dispute resolution mechanism in an international joint venture requires forward thinking, say Jens Petry and Tom Gassmann, Squire Patton Boggs. 22 February 2024
Americas
US Patent and Trademark Office publishes ‘clear’ guidance mandating AI-related patents to have ‘significant’ human involvement | Cites one hypothetical example relating to the development of a compound for treating cancer | Kathi Vidal: ‘patent system was developed to incentivise and protect human ingenuity’. 13 February 2024
Biotech
Biotech claims action was necessary due to unfavourable rulings after being targeted by a rival | Accuses gene technology firm of attempting to shrink the competitive landscape for different spatial biology platforms. 6 February 2024
Pharma
PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation. 1 February 2024
Americas
Pharma giants raise concerns about Moderna’s COVID-19 vaccine patents | Company's statements to the FDA and PTAB contain "inconsistencies" | Appeals Board urged to scrutinise assertions. 1 February 2024